GREENFIELD, Ind, Nov. 25, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
On Tuesday, December 3, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Evercore ISI 7th Annual HealthCONx at 11:15 a.m. ET.
On Thursday, December 5, Todd Young will participate in the Piper Sandler 36th Annual Healthcare Conference at 1:30 p.m. ET.
Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will be available for approximately 30 days.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Investor Contact: Katy Grissom (317) 273-9284 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Colleen Parr Dekker (317) 989-7011 This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$13.44 |
| Daily Change: | -0.08 -0.59 |
| Daily Volume: | 6,083,784 |
| Market Cap: | US$6.640B |
February 25, 2025 February 25, 2025 November 15, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
